ArticlePharmacoEconomics2020

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data.

Koen Degeling et al.PubMed ↗Publisher ↗

No numbers read from the abstract.